Lanean...
Daclizumab high-yield process in the treatment of relapsing–remitting multiple sclerosis
Daclizumab is a humanized monoclonal antibody that binds to the α subunit (CD25) of the interleukin-2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56(bright) natural k...
Gorde:
| Argitaratua izan da: | Ther Adv Neurol Disord |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5400154/ https://ncbi.nlm.nih.gov/pubmed/28450896 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285616671887 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|